On this page of StockholderLetter.com we present the latest annual shareholder letter from Aptevo Therapeutics Inc. — ticker symbol APVO. Reading current and past APVO letters to shareholders can bring important insights into the investment thesis.
2023 ANNUAL REPORT
To My Fellow Shareholders, / on where we are as a K ^ . F (DoR) from our WsK W d data d D> and the only . The DoR data, out- , APVO436 has -of- D> ^ WsK h W FDA to D> . t well t W D> d W - W quarter d d WsK owest C Release Syndrome (CRS) - . / Z^ WsK of the syndrome d WsK we / WsK Z^ d one- h we W t WsK d D> / Wd/Z - the
>' Ws- , our 4- d - d t a Phase 1 t D >' Ws- WsK d and that of our - ^ d d also ur a s. >' Ws- d- t K - WsK d t x x x WsK d WsK d In vivo WsK W -> -
d . D t t t D> t the story ^ d are that we are for d / / WsK and d >' Ws- W t >' Ws- t on our WsK relevant to / > The best way to predict your future is to create it d D t W K d
 • shareholder letter icon 4/23/2024 Letter Continued (Full PDF)
 • stockholder letter icon 4/18/2023 APVO Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon APVO Benford's Law Stock Score = 75


APVO Shareholder/Stockholder Letter Transcript:

2023 ANNUAL REPORT


To My Fellow Shareholders,
                                                            /                                                          on where we are as a
K                                                                                                                                                        ^            
                              . F                                                                                                               (DoR) from our
 WsK       W                                                        d       data                                                                     
                                                 d                                                                         D>              and the only
                                         . The DoR data,                                                                                                              
                         out-                                                                   ,                                               APVO436 has
                                                                              -of-                                                        D>                
^                                  WsK                                            h                                               W                              
                                            FDA to                                                                                                               
                                                          D>                              . t                                                                    
well                                                                                   
t                                  W                                                      D>                                                                            
                              d                                        W                                                                          -             
W                                                                                    quarter    d                                                                           
                                                                       d                                                                                             
 WsK                                                                                         owest                                                                 
C               Release Syndrome (CRS)                                                               -                                        .
/                                                                                                                  Z^         WsK                               
                                                                                         of the syndrome    d                                       
 WsK                                                               we                                                                                 /                     
                                                          WsK                                                      Z^    d                                       
one-                                                                                                         h                                                 
                                  we                                 W                        
t                                                               WsK                         d                                                                
                                                                                   D>    /                                                                            
                                           Wd/Z                                                                    -                                                 
                                     the                                                             

 >'   Ws-      , our 4-          d       -                                                                                                                  
                                                                                                                         d      t                    a Phase 1

t                                                                          D                                 >'   Ws-                   WsK                         
                               d                           and                                                     that                               
                     of our                                                                                                                                  
                                                   -                                           ^                                      d                         
                                                                                                              d                                                            

           also                                                                                                                                                         
                          ur a                                                                                                                

                                      s.
 >'   Ws-                                                                                                                                                 
                                                                                                                                    d-                                                                                                                                                                                                
t                                                                                                                                                                       
                                                                        K                                                                      -                                      
 WsK          d                                                                                                                                                       
                                                                                                                            t                                     
x
x
x
 WsK                                                                                                                            d                                
                                                                                           WsK                                                                d 
In vivo                                                    WsK                                           W ->  -                                  

d                                                               . D                                                                                          
                                                                                                      t                                                            
                                                                     t                                                                                               
                                 t                                                                                                                                     
                                                              D>                                                                   t                         
                                                                           the story    ^                                                                             

d                                                        are that we are                                                                               
                 for                                                                                                                                          d                

/                                                                                                                                   /           WsK       
                                                                                                                         and                                      
                                                          d      >'   Ws-       W                                                                                  
                                                                                                                                                             t            
                                                                                                         >'   Ws-                                                            
                                                 t                                                                                                                          
on our                                                                       WsK                                                                                     
                                                        relevant to                        
/                                                                         >                                 The best way to predict your future
is to create it      d                                                                                                                                           

D           t        
W                          K
            d                    



shareholder letter icon 4/23/2024 Letter Continued (Full PDF)
 

APVO Stockholder/Shareholder Letter (Aptevo Therapeutics Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.